Antibodies targeting talaromyces marneffei mp1p protein and methods of use thereof
US-2024199726-A1 · Jun 20, 2024 · US
Epigenetic co-repressors of the gamma-globin gene and methods of using same
US8975293B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8975293-B2 |
| Application number | US-201213480036-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 24, 2012 |
| Priority date | May 26, 2011 |
| Publication date | Mar 10, 2015 |
| Grant date | Mar 10, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure describes methods of screening for compounds that disrupt the interaction between DNMT1 and the gamma-globin promoter or between LSD-1 and the gamma-globin promoter. This disclosure describes methods of screening for compounds that de-repress the gamma-globin gene.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of screening for compounds that stimulate expression of a gamma-globin gene, wherein said method comprises the steps of: contacting a recombinant non-erythroid host cell with a test compound, wherein the recombinant non-erythroid host cell comprises an exogenous nucleic acid sequence encoding a DNA methyltransferase I (DNMT1) polypeptide and a nucleic acid sequence encoding a detectable polypeptide operably linked to a human gamma-globin gene promot…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Physics · mapped topic
Human Necessities · mapped topic
Physics · mapped topic
Physics · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8975293B2 cover?
- This disclosure describes methods of screening for compounds that disrupt the interaction between DNMT1 and the gamma-globin promoter or between LSD-1 and the gamma-globin promoter. This disclosure describes methods of screening for compounds that de-repress the gamma-globin gene.
- Who is the assignee on this patent?
- Engel James Douglas, Tanabe Osamu, Shi Lihong, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6854. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Mar 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).